Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock

$27.04

1.49% yesterday

NYSE, Jul 11, 10:10 pm CET

ISIN

US3580291066

Symbol

FMS

Reports

Quarter | Annual

Index

CDAX, NYSE Composite

Sector

Health

Industry

Health service provider

Overview Dividends Analysts Charts News Strategies

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock price

$27.04

-14.60 35.06% 5Y

NYSE, Closing price Fri, Jul 11 2025

-0.41 1.49%

ISIN

US3580291066

Symbol

FMS

Reports

Quarter | Annual

Index

CDAX, NYSE Composite

Sector

Health

Industry

Health service provider

Key metrics

Basic

Market capitalization

$16.1b

Enterprise Value

$27.0b

Net debt

$10.9b

Cash

$1.7b

Shares outstanding

293.4m

Valuation (TTM | estimate)

P/E

11.0 | 6.2

P/S

0.7 | 0.7

EV/Sales

1.2 | 1.2

EV/FCF

13.7

P/B

1.0

Dividends

DPS

$0.81

Yield 1Y | 5Y

3.0% | 2.8%

Growth 1Y | 5Y

26.8% | 2.6%

Payout 1Y | 3Y

30.0% | 28.7%

Increased

2 Years

Financials (TTM | estimate)

Revenue

$22.8b | $23.2b

EBITDA

$3.5b | $4.3b

EBIT

$1.6b | $2.5b

Net Income

$722.6m | $1.3b

Free Cash Flow

$2.0b

Growth (TTM | estimate)

Revenue

0.1% | 2.7%

EBITDA

-2.8% | 21.6%

EBIT

9.0% | 66.1%

Net Income

27.8% | 102.1%

Free Cash Flow

-11.8%

Financial Health

Equity Ratio

43.4%

Return on Equity

3.7%

ROCE

5.1%

ROIC

3.6%

Debt/Equity

0.8

EPS

$2.5

FCF per Share

$6.7

Short interest

0.2%

Employees

112k

Rev per Employee

$200.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock Analysis

Unlock Scores for Free

??

25 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:

9x Buy

36%

12x Hold

48%

4x Sell

16%

More details on Analyst Estimates Including Price Targets

25 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:

Buy

36%

Hold

48%

Sell

16%

Analyst Estimates with Stock Price Targets

Financial data from Fresenius Medical Care AG & Co. KGaA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	22,785 22,785	0% 0% 100%
- Direct Costs	17,213 17,213	1% 1% 76%
Gross Profit	5,572 5,572	4% 4% 24%
- Selling and Administrative Expenses	3,644 3,644	2% 2% 16%
- Research and Development Expense	209 209	19% 19% 1%
EBITDA	3,533 3,533	3% 3% 16%
- Depreciation and Amortization	1,899 1,899	11% 11% 8%
EBIT (Operating Income) EBIT	1,635 1,635	9% 9% 7%
Net Profit	723 723	28% 28% 3%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock News

Neutral

PRNewsWire

●

9 days ago

Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico

High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States BAD HOMBURG, Germany , July 3, 2025 /PRNewswire...

Positive

WSJ

●

25 days ago

Fresenius Medical Care CEO Says Company Could Benefit From Obesity Drugs

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive' rather than negative.

Neutral

PRNewsWire

●

25 days ago

Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation

FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovation The Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plans Profitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 margins FME25+ savings target expanded by EUR 300 million...

More Fresenius Medical Care AG & Co. KGaA Sponsored ADR News

Company Profile

Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Head office	Germany
CEO	Helen Giza
Employees	111,513
Founded	1996
Website	www.freseniusmedicalcare.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now